Iovance Biotherapeutics (IOVA) Interest Coverage Ratio (2011 - 2026)
Iovance Biotherapeutics (IOVA) posted quarterly Interest Coverage Ratio of 0.03 for Q1 2026, up 99.43% year-over-year from 0.02 in Q1 2025, and up 99.83% quarter-over-quarter from 18.98 in Q4 2025.
Powered by 
Analysis
Iovance Biotherapeutics (IOVA) Interest Coverage Ratio (2011 - 2026) Analysis & Trends
Iovance Biotherapeutics (IOVA) has reported Interest Coverage Ratio for 16 consecutive years, with 0.03 the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest Coverage Ratio rose 99.43% year-over-year to 0.03; the TTM figure through Mar 2026 stood at 0.14 (up 99.22% YoY), while the FY2025 annual figure was 0.45, up 89.36% from the prior year.
- Interest Coverage Ratio advanced to 0.03 in Q1 2026 per IOVA's latest filing, from 18.98 in the prior quarter.
- Across five years, Interest Coverage Ratio topped out at 14.74 in Q4 2022 and bottomed at 30.57 in Q2 2022.
- Historically, Interest Coverage Ratio has averaged 6.26 across 5 years, with a median of 3.32 in 2022.
- Annual changes were most pronounced in 2023 — Interest Coverage Ratio soared 99.44% — and 2024, when it sank 9510.01%.
- Iovance Biotherapeutics' Interest Coverage Ratio stood at 14.74 in 2022, then retreated by 4.39% to 14.09 in 2023, then sank by 222.0% to 17.19 in 2024, then slipped by 10.36% to 18.98 in 2025, then surged by 99.83% to 0.03 in 2026.
- Business Quant data shows IOVA's Interest Coverage Ratio at 0.03 in Q1 2026, 18.98 in Q4 2025, and 0.61 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -493.00 |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -21.24 |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 8.18 |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 2.82 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 1.42 |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.08 |
| 10 | Iovance Biotherapeutics | 3.95 Bn | 3.66 Bn | 55.72 Mn | -0.01 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -0.01 |
| Mar 31, 2026 | -0.03 |
| Sep 30, 2025 | -0.61 |
| Sep 30, 2012 | -12.82 |
| Jun 30, 2012 | -14.86 |
| Mar 31, 2012 | -35.45 |
| Dec 31, 2011 | -34.91 |
| Sep 30, 2011 | -183.74 |